About Legend Biotech Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://investors.legendbiotech.com/
Frequently Asked Questions
What is the 52-week range for LEGN?
The 52-week high is $37.5 and the 52-week low is $16.24.
What is the P/E ratio for LEGN?
The P/E ratio data is currently unavailable.
What is the dividend yield for LEGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -8.70%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7.20%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.97.
Analyst Recommendation Trends
Wall Street analyst consensus for LEGN over the last few months:
Latest LEGN News
Sector Update: Healthcare Stocks Steady Late Afternoon
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare profess
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Asian equities traded in the US as American depositary receipts were lower on Tuesday morning, decre
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced five-year follow-up data from CARTITUDE-2 Cohort A (n=20) evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) after one t
Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?
Legend Biotech (NASDAQ:LEGN) presents a compelling equity thesis centered on transforming breakthrough oncology innovation into a high-margin, cash-generative cell therapy franchise. Maintaining a fortress balance sheet anchored by approximately $965 million in cash, cash equivalents, and time deposits as of June 30, fortified by $212 million in net proceeds from a public offering of American […]
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Execut
Legend Naming Novartis Executive as CEO
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
'Legend Naming Novartis Executive as CEO' - Wall Street Journal
https://www.wsj.com/health/pharma/legend-naming-novartis-executive-as-ceo-6a79fa0c
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapyReal-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd I
Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | Sanders Corazon (Corsee) D. | -27,370 | $9.46 | $258,920 |
| 2026-09-24 | Mao Li | +20,986 | - | - |
| 2026-09-24 | Salovey Peter | +28,330 | - | - |
| 2026-09-24 | Casey Patrick John | +20,986 | - | - |
| 2026-09-24 | Ji Darren Xiaohui | +28,330 | - | - |
| 2026-09-24 | Heyman Tomas J. | +20,986 | - | - |
| 2026-09-24 | Sanders Corazon (Corsee) D. | +20,986 | - | - |
| 2026-09-21 | Santos Carlos E | -5,430 | $9.14 | $49,630 |
| 2026-09-21 | Santos Carlos E | +19,676 | - | - |
| 2026-09-15 | Zhang Ingrid | +1,131,860 | - | - |
| 2026-08-14 | BASH ALAN | +4,908 | - | - |
| 2026-06-30 | Casey Patrick John | -6,000 | $14.8 | $88,800 |
| 2026-06-30 | Huang Ying | -3,382 | - | - |
| 2026-03-25 | Huang Ying | -9,936 | $8.77 | $87,139 |